AC
RPRX

Ascend Capital’s Repros Therapeutics Inc. RPRX Stock Holding History

Ascend Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-40,000
Closed -$343K – 224
2015
Q1 		$343K Buy
+40,000
New +$358K 0.01% 161
2013
Q3 		– Sell
-87,711
Closed -$1.62M – 272
2013
Q2 		$1.62M Buy
+87,711
New +$1.55M 0.07% 155

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

Ascend Capital's RPRX Position: Q2 2015 in Review

Ascend Capital sold out of Repros Therapeutics Inc. (RPRX) in Q2 2015, closing a stake of 40,000 shares — an estimated $343K sold.

Ascend Capital first reported a position in RPRX in Q2 2013 and held it in 2 quarters. The position peaked at $1.62M in Q2 2013. 64 funds tracked by Wall St. Rank hold RPRX as of Q2 2015.

  • Ascend Capital reported no remaining Repros Therapeutics Inc. position as of Q2 2015 after selling out during the quarter.
  • Ascend Capital sold 40,000 Repros Therapeutics Inc. shares in Q2 2015, an estimated $343K.
  • Ascend Capital first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 2 quarters.
  • Ascend Capital's Repros Therapeutics Inc. position peaked at $1.62M in Q2 2013.
  • 64 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2015.

Based on Ascend Capital's 13F filing for Q2 2015, filed 13 Aug 2015.